US 12,144,812 B2
Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
Yip-Fong Chia, Menlo Park, CA (US); Stephen Arboleda, Menlo Park, CA (US); Yan Alsmeyer, Menlo Park, CA (US); Gordon Davis, Menlo Park, CA (US); and Tyler Clikeman, Menlo Park, CA (US)
Assigned to Corcept Therapeutics Incorporated, Redwood City, CA (US)
Filed by CORCEPT THERAPEUTICS INCORPORATED, Menlo Park, CA (US)
Filed on May 5, 2021, as Appl. No. 17/308,376.
Claims priority of provisional application 63/020,919, filed on May 6, 2020.
Prior Publication US 2021/0361651 A1, Nov. 25, 2021
Int. Cl. A61K 31/513 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/513 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2095 (2013.01)] 15 Claims
 
1. A composition comprising:
Compound I, (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione:

OG Complex Work Unit Chemistry
in an amount from 20.0 to 28.0% (w/w);
a poly[(methyl methacrylate)-co-(methacrylic acid)] in an amount from 20.0 to 28.0% (w/w);
sodium lauryl sulfate in an amount from 0.5 to 5.0% (w/w);
a sustaining polymer which is hydroxypropyl methylcellulose acetate succinate (HPMCAS), in an amount from 10.0 to 28.0% (w/w);
microcrystalline cellulose in an amount from 10.0 to 25.0% (w/w); and
croscarmellose sodium (Ac-Di-Sol) in an amount from 5.0 to 11.0% (w/w).